External Committees

Advisory Board

The ICER Advisory Board is comprised of Flagship members of ICER’s Policy Leadership Forum and other select stakeholders. The Advisory Board meets annually with ICER’s Governance Board to provide guidance on ICER’s overall portfolio of activities and strategic plan. The Advisory Board provides perspective and advice to ICER on how it can best fulfill its mission, but the Advisory Board has no direct governance role.

  • Lora Armstrong, PharmD, Vice President, Medical Affairs, CVS Health
  • Carmella Bocchino, RN, MBA , President and CEO, CRB Strategies, LLC
  • Victoria Brown, PharmD, AVP, Clinical Drug Strategy, Humana
  • Michael A. Evans, RPh, MBA, FASHP, Vice President & Chief Pharmacy Officer, Geisinger Health System
  • Patrick Gleason, PharmD, Assistant Vice President, Health Outcomes, Prime Therapeutics
  • Andreas Kuznik, PhD, Executive Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc.
  • Kim Le, PharmD, Vice President, National Clinical Pharmacy Services, Kaiser Permanente
  • Julia Logan, MD, MPH, Chief Clinical Director, California Public Employees’ Retirement System (CalPERS)
  • Jaclyn Martin, MBA, MPH, Vice President, Market Access and Patient Services, Intellia Therapeutics
  • Mark McClellan, MD, PhD, Founding Director, Duke-Margolis Center for Health Policy, Duke University
  • Megan McIntyre, PharmD, Vice President, Pharmacy and Clinical Consulting, Premera Blue Cross
  • Luke Prettol, Principal Benefits Strategy Consultant, AT&T
  • Lindsay Rippelmeyer, PharmD, Senior Director, Supply Chain Finance, Express Scripts
  • Craig Roberts, PharmD, MBA, Vice President, Vaccines, Value and Implementation, Outcomes Research, Merck & Co., Inc.
  • Mark Shinmoto, PharmD, Vice President and Chief Pharmacy Officer, Ventegra
  • Sean D. Sullivan, PhD, Professor and Dean, University of Washington School of Pharmacy
  • Kimberly Westrich, Chief Strategy Officer, National Pharmaceutical Council
  • Tiffany Westrich-Robertson, ICER Patient Council Co-Chair; CEO, International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis)
  • Sarah Yoon, Director of Drug Information, Centene Pharmacy Services

Methods Advisory Group

ICER’s Methods Advisory Group (MAG) meets three times per year to provide guidance on ICER’s methods for health technology assessments and other evaluations. In the past few years, the MAG has helped to shape a data in-confidence policy, develop a pilot for a model transparency program, and comment on the process and methods for ICER’s report evaluating price increases for high impact drugs.

  • AT&T
  • California Public Employees’ Retirement System (CalPERS)
  • Centene Pharmacy Services
  • CVS Caremark
  • Express Scripts
  • Geisinger Health System
  • Humana
  • Intellia Therapeutics
  • Kaiser Permanente
  • Merck & Co.
  • National Pharmaceutical Council
  • Premera Blue Cross
  • Prime Therapeutics
  • Regeneron Pharmaceuticals, Inc.
  • Ventegra
  • Jeffrey A. Tice, MD, Department of Medicine, Division of General Internal Medicine, University of California